WallStreetZenWallStreetZen

NASDAQ: ALT
Altimmune Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ALT

Based on 3 analysts offering 12 month price targets for Altimmune Inc

Min Forecast
$10.00+205.81%
Avg Forecast
$13.67+317.95%
Max Forecast
$20.00+511.62%

Should I buy or sell ALT stock?

Based on 3 analysts offering ratings for Altimmune Inc.

Buy
Strong Buy
0 analysts 0%
Buy
3 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ALT's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates ALT as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their ALT stock forecasts and price targets.

ALT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-22
lockedlocked$00.00+00.00%2026-05-18
lockedlocked$00.00+00.00%2026-05-14

1 of 1

Forecast return on equity

Is ALT forecast to generate an efficient return?

Company
-42.12%
Industry
19.23%
Market
167.69%
ALT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ALT forecast to generate an efficient return on assets?

Company
-37.89%
Industry
25.59%
ALT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ALT earnings per share forecast

What is ALT's earnings per share in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
-$0.59
Avg 2 year Forecast
-$0.65
Avg 3 year Forecast
-$0.76

ALT revenue forecast

What is ALT's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$0.0-100%
Avg 2 year Forecast
$0.0-100%
Avg 3 year Forecast
$0.0-100%
ALT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ALT revenue growth forecast

How is ALT forecast to perform vs Biotechnology companies and vs the US market?

Company
-100%
Industry
32.79%
Market
13.21%
ALT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ALT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ALT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ALT$3.27$13.67+317.95%Buy
AGMB$13.06$43.00+229.25%Strong Buy
KZIA$11.19$31.33+180.01%Strong Buy
VALN$6.66N/AN/A
STTK$6.20$14.86+139.63%Strong Buy
View Top Biotech Stocks

Altimmune Stock Forecast FAQ

Is Altimmune Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: ALT) stock is to Buy ALT stock.

Out of 3 analysts, 0 (0%) are recommending ALT as a Strong Buy, 3 (100%) are recommending ALT as a Buy, 0 (0%) are recommending ALT as a Hold, 0 (0%) are recommending ALT as a Sell, and 0 (0%) are recommending ALT as a Strong Sell.

If you're new to stock investing, here's how to buy Altimmune stock.

What is ALT's earnings growth forecast for 2026-2028?

(NASDAQ: ALT) Altimmune's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.06%.

Altimmune's earnings in 2026 is -$91,760,000.On average, 11 Wall Street analysts forecast ALT's earnings for 2026 to be -$115,096,124, with the lowest ALT earnings forecast at -$123,907,776, and the highest ALT earnings forecast at -$108,249,101. On average, 11 Wall Street analysts forecast ALT's earnings for 2027 to be -$125,969,663, with the lowest ALT earnings forecast at -$168,705,202, and the highest ALT earnings forecast at -$89,867,178.

In 2028, ALT is forecast to generate -$147,619,483 in earnings, with the lowest earnings forecast at -$242,096,731 and the highest earnings forecast at -$89,867,178.

What is ALT's revenue growth forecast for 2026-2028?

(NASDAQ: ALT) Altimmune's forecast annual revenue growth rate of -100% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.21%.

Altimmune's revenue in 2026 is $31,000.On average, 11 Wall Street analysts forecast ALT's revenue for 2026 to be $0, with the lowest ALT revenue forecast at $0, and the highest ALT revenue forecast at $0. On average, 11 Wall Street analysts forecast ALT's revenue for 2027 to be $0, with the lowest ALT revenue forecast at $0, and the highest ALT revenue forecast at $0.

In 2028, ALT is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is ALT's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ALT) forecast ROA is -37.89%, which is lower than the forecast US Biotechnology industry average of 25.59%.

What is ALT's Price Target?

According to 3 Wall Street analysts that have issued a 1 year ALT price target, the average ALT price target is $13.67, with the highest ALT stock price forecast at $20.00 and the lowest ALT stock price forecast at $10.00.

On average, Wall Street analysts predict that Altimmune's share price could reach $13.67 by Jun 22, 2027. The average Altimmune stock price prediction forecasts a potential upside of 317.95% from the current ALT share price of $3.27.

What is ALT's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ALT) Altimmune's current Earnings Per Share (EPS) is -$0.77. On average, analysts forecast that ALT's EPS will be -$0.59 for 2026, with the lowest EPS forecast at -$0.64, and the highest EPS forecast at -$0.56. On average, analysts forecast that ALT's EPS will be -$0.65 for 2027, with the lowest EPS forecast at -$0.87, and the highest EPS forecast at -$0.46. In 2028, ALT's EPS is forecast to hit -$0.76 (min: -$1.24, max: -$0.46).

What is ALT's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ALT) forecast ROE is -42.12%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.